mlys: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	494,298	199,110
Net increase in cash and cash equivalents	103,506	-12,303
Cash and cash equivalents at beginning of period	114,091	-
Cash and cash equivalents at end of period	217,597	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	494,298	199,110
Net increase in cash and cash equivalents	103,506	-12,303
Cash and cash equivalents at beginning of period	114,091	-
Cash and cash equivalents at end of period	217,597	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Mineralys Therapeutics, Inc. (MLYS)